<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1560">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05525780</url>
  </required_header>
  <id_info>
    <org_study_id>G2GBio</org_study_id>
    <nct_id>NCT05525780</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 IM Depot and Aricept® Oral Tablets in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Donepezil From Single Dose of GB-5001 Intramuscular Depot and Aricept® Oral Tablets (Pfizer Canada Inc.) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G2GBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G2GBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil)&#xD;
      IM depot in healthy male volunteers. And, it is to predict the multiple-dose pharmacokinetics&#xD;
      based on the single-dose pharmacokinetics of GB-5001 IM depot and the oral Aricept®&#xD;
      (donepezil hydrochloride) tablet by PK modeling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity, and dose-relationship of AEs</measure>
    <time_frame>Day 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Day 64</time_frame>
    <description>blood pressure [BP], respiratory rate [RR], heart rate [HR], and temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>Day 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Day 64</time_frame>
    <description>Height, weight, and BMI will be recorded</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Injection site assessments</measure>
    <time_frame>Day 64</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key PK parameters for single dose IM and Oral cohorts</measure>
    <time_frame>Day 64</time_frame>
    <description>AUCt: area under the plasma concentration vs time curve from time 0 to the time of the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key PK parameters for single dose IM and Oral cohorts</measure>
    <time_frame>Day 64</time_frame>
    <description>Cmax: maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key PK parameters for single dose IM and Oral cohorts</measure>
    <time_frame>Day 64</time_frame>
    <description>tmax: time to maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key PK parameters for single dose IM and Oral cohorts</measure>
    <time_frame>Day 64</time_frame>
    <description>λz: terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key PK parameters for single dose IM and Oral cohorts</measure>
    <time_frame>Day 64</time_frame>
    <description>t½: terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>GB-5001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB-5001 Suspension for intramuscular (IM) injection at three doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Suspension for intramuscular (IM) injection, Volume to be matched with the active drug in the respective cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aricept® tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB-5001</intervention_name>
    <description>Depending on the cohort, volume will be varied to administer.</description>
    <arm_group_label>GB-5001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A matched volume of placebo product will be administered to each subject in each cohort.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral cohort</intervention_name>
    <description>Single dose of Aricept tablet</description>
    <arm_group_label>Oral cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, non-smoking male volunteers, 18-55 years of age, inclusive at the time of&#xD;
             informed consent.&#xD;
&#xD;
          -  Body mass index (BMI) that is within 18.5 - 30.0 kg/m2, inclusive, and weight at least&#xD;
             55 kg and above.&#xD;
&#xD;
          -  Healthy, according to the medical history, ECG, vital signs, laboratory results and&#xD;
             physical examination as determined by the PI/Sub-Investigator.&#xD;
&#xD;
          -  Systolic blood pressure between 95-140 mmHg, inclusive, and diastolic blood pressure&#xD;
             between 55-90 mmHg, inclusive, and heart rate between 60-100 bpm, inclusive, unless&#xD;
             deemed otherwise by the PI/Sub-Investigator.&#xD;
&#xD;
          -  Clinical laboratory values within the clinical site's most recent acceptable&#xD;
             laboratory test range, and/or values are deemed by the PI/Sub-Investigator as &quot;Not&#xD;
             Clinically Significant&quot;.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history or presence of any clinically significant hepatic, renal/genitourinary,&#xD;
             gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine,&#xD;
             immunological, musculoskeletal, neurological, psychiatric, dermatological or&#xD;
             hematological disease or condition unless determined as not clinically significant by&#xD;
             the PI/Sub-Investigator.&#xD;
&#xD;
          -  Known history or presence of seizure or convulsion, unless determined as not&#xD;
             clinically significant by the PI/Sub-Investigator.&#xD;
&#xD;
          -  Known history or presence of peptic ulcer or gastrointestinal bleeding within 3 months&#xD;
             prior to study drug administration, unless determined as not clinically significant by&#xD;
             the PI/Sub-Investigator.&#xD;
&#xD;
          -  Known risk of developing ulcers (for example, if you are taking non-steroidal&#xD;
             anti-inflammatory drugs [NSAIDS] or high doses of acetylsalicylic acid [ASA]&#xD;
             [Aspirin®]), unless determined as not clinically significant by the&#xD;
             PI/Sub-Investigator.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease),&#xD;
             unresolved gastrointestinal symptoms, or other conditions known to interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of the drug experienced within 7&#xD;
             days prior to study drug administration, as determined by the PI/Sub-Investigator.&#xD;
&#xD;
          -  Presence of any clinically significant illness within 30 days prior to dosing, as&#xD;
             determined by the PI/Sub-Investigator&#xD;
&#xD;
          -  Presence of any clinically significant illness within 30 days prior to dosing, as&#xD;
             determined by the PI/Sub-Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Na-Yeon Park</last_name>
    <phone>82-2-400-2694</phone>
    <email>na-yeon.park@g2gbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shin-Won Lee</last_name>
    <phone>82-2-6956-2698</phone>
    <email>shin-won.lee@g2gbio.com</email>
  </overall_contact_backup>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>August 23, 2022</study_first_submitted>
  <study_first_submitted_qc>August 30, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2022</study_first_posted>
  <last_update_submitted>August 30, 2022</last_update_submitted>
  <last_update_submitted_qc>August 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

